⁶⁴Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies

Abstract

The preliminary results of this study demonstrate the high potential of Cu-PSMA ligand PET/CT imaging in patients with recurrent disease and in the primary staging of selected patients with progressive local disease. The acquired PET images showed an excellent resolution of the detected lesions with very high lesion-to- background contrast. Furthermore, the long half-life ofCu allows distribution of the tracer to clinical PET centers that lack radiochemistry facilities for the preparation of Ga-PSMA ligand (satellite concept).

Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging

“…Clinical studies have increasingly confirmed that PSMA is a valuable target for both the diagnosis and the treatment of prostate cancer (4,5). Radiolabeled urea derivatives, including 18 F-DCFBC (6), 18 F-DCFPyL (7), 68 Ga-PSMA-HBED-CC (8), 99m Tc-MIP-1404 (9), 68 Ga/ 64 Cu-DKFZ-PSMA-617 (10)(11)(12), and 18 F-PSMA-1007 (13,14), have been reported to detect primary and metastatic prostate cancer lesions. PSMA PET imaging improves the detection rates for metastatic lesions in lymph nodes and bone, especially at low prostate-specific antigen levels (14)(15)(16)(17)(18)(19)(20).…”

Implementation of a new separation method to produce qualitatively improved 64Cu

“…It has been shown that 64 Cu is suited in combination with diacetyl‐bis(N(4))‐methylthiosemicarbazone (ATSM) and with various tumor‐targeting peptides . This has been exemplified by the use of the radionuclide with somatostatin analogs and prostate‐specific membrane antigen (PSMA), respectively. As it is believed that the radionuclide would be particularly suited for biomolecules with slow in vivo kinetics and delayed tumor accumulation, it may also be combined with plasma protein‐binding ligands such as recently exemplified with albumin‐binding folate conjugates and PSMA ligands .…”

Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy

“…The first was 64 Cu for PET imaging in the course of a clinical study. 173 Another study tested whether 44 Sc would be a feasible alternative to 68 Ga as a diagnostic match to 177 Lu-PSMA-617. 174 44 Sc has a fourfold longer half-life than 68 Ga and is also a nuclide suitable for PET imaging.…”